Overview Request Sample Pages Request Customization Download PDF
You are viewing: Europe Cardiac Marker Testing Market analysis
Part of: Cardiac Marker Testing Market (Global)

The Europe Cardiac Marker Testing Market was valued at $861.5 Million in 2026 and projected to reach to $1494.9 Million by 2031, representing a compound annual growth rate of 11.7%. Europe's cardiac marker testing market is positioned for substantial growth through 2031, driven by an aging population increasingly susceptible to cardiovascular diseases and rising healthcare expenditures across the region.

Europe Cardiac Marker Testing Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Cardiac Marker Testing Market Trends and Insights

  • This growth trajectory reflects Europe's aging population, rising prevalence of cardiovascular diseases, and increasing adoption of advanced diagnostic technologies across the region.
  • Europe's healthcare infrastructure and regulatory frameworks support widespread implementation of cardiac biomarker testing in both hospital and point-of-care settings. The European market benefits from strong reimbursement policies, high healthcare spending, and a growing emphasis on early cardiac disease detection.
  • Between 2026 and 2031, Europe is expected to witness accelerated demand for high-sensitivity troponin assays and multiplex testing platforms.
  • Europe's commitment to cardiovascular health initiatives and integration of cardiac markers into clinical guidelines further drive market penetration across cardiology, emergency medicine, and primary care sectors..

Key Market Statistics

  • CAGR (2026-2031) 11.7% CAGR
  • Market Size, 2026 ~USD 861.5 Million
  • Forecast, 2031 ~USD 1494.9 Million
  • Geography Europe

Europe Cardiac Marker Testing Market Overview

Market Valuation & Growth :

Europe's cardiac marker testing market is valued at $861.5 million in 2026, with a robust CAGR of 11.7%, significantly outpacing the global growth rate of 10.3%, demonstrating strong regional momentum.

Aging Population Dynamics :

Europe's rapidly aging demographic profile is driving increased cardiovascular disease prevalence, creating sustained demand for advanced cardiac diagnostic solutions and early detection technologies across the region.

Healthcare Infrastructure Strength :

Europe's well-established healthcare systems, stringent regulatory frameworks, and high adoption rates of advanced diagnostic technologies create an ideal environment for cardiac marker testing market expansion.

2031 Market Projection :

The market is forecasted to reach $1,494.9 million by 2031, representing a 73.5% increase from 2026, reflecting sustained investment in cardiovascular diagnostics and healthcare modernization across European nations.

Europe Cardiac Marker Testing Market Dynamics

  • The continent's advanced healthcare infrastructure, coupled with strong regulatory support and high adoption of innovative diagnostic technologies, creates favorable conditions for market expansion.
  • Key European markets including Germany, France, and Italy are leading this growth trajectory. The forecast period will witness accelerated adoption of high-sensitivity troponin assays, point-of-care testing solutions, and integrated diagnostic platforms.
  • Healthcare providers across Europe are prioritizing early cardiac event detection and risk stratification, driving demand for sophisticated marker testing solutions.
  • Continued investment in healthcare digitalization and personalized medicine approaches will further propel market growth through 2031..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
    Top Companies

      Medical Devices

      Top Technologies
        Top Companies

          Key Takeaways

          • Europe's cardiac marker testing market will grow from $861.5M (2026) to $1,494.9M (2031) at an 11.7% CAGR.
          • Europe's aging demographics and high cardiovascular disease burden are primary growth catalysts for cardiac marker adoption.
          • Europe's robust healthcare infrastructure and reimbursement systems enable widespread clinical implementation of advanced cardiac biomarker assays.
          • Europe is shifting toward high-sensitivity troponin and multiplex testing platforms, driving innovation and market expansion through 2031.

          Cardiac Marker Testing Market Report Scope

          Report Metric Details
          Base Year 2026
          Fastest Growing Segment OTHER CARDIAC BIOMARKERS (Biomarker Type)
          Forecast Period 2026–2031
          Growth Rate CAGR of 10.3% from 2026 to 2031
          Largest Segment SINGLEPLEX ASSAY (Assay Format)
          Market Size Base Year (Billions) ~USD 5.55 (2026)
          Revenue Forecast (Billions) ~USD 9.06 (2031)
          Segments Covered Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User

          Europe Cardiac Marker Testing Market Report Segmentation

          8 segment dimensions are covered across the global market.

          By Product

          • Instruments
          • Reagents & Kits

          By Technology

          • Clinical Chemistry
          • Immunoassay
          • Immunoassays

          By Type

          • Chemiluminescence
          • Contract Testing Laboratories
          • Elisa
          • Hospital Laboratories
          • Immunofluorescence
          • Lateral Flow Immunoassay
          • Reference Laboratories

          By Indication

          • Acute Coronary Syndrome
          • Atherosclerosis
          • Congestive Heart Failure
          • Ischemia
          • Myocardial Infarction

          By Biomarker Type

          • Brain Natriuretic Peptide
          • Creatinine Kinase-Mb
          • High-Sensitivity C-Reactive Protein
          • Homocysteine
          • Myoglobin
          • Other Cardiac Biomarkers
          • Troponin I & T

          By Point Of Testing

          • Lab Tests
          • Poc Tests

          By Assay Format

          • Multiplex Assay
          • Multiplex Assays
          • Singleplex Assay
          • Singleplex Assays

          By End User

          • Academic Institutes
          • Laboratory Testing Facilities
          • Point-Of-Care Testing

          REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031

          Segment20242025202620272028202920302031CAGR (%)
          ACADEMIC INSTITUTES10.11010.611.21212.813.714.76.9
          LABORATORY TESTING FACILITIES74.172.57679.984.489.595.1101.25.9
          POINT-OF-CARE TESTING22.822.724.3262830.332.835.67.9
          TOTAL107105.2110.9117.2124.4132.5141.6151.56.4

          EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031

          Segment20242025202620272028202920302031CAGR (%)
          ACADEMIC INSTITUTES141.9146.1161.4178.6198.5221.5247.9277.711.5
          LABORATORY TESTING FACILITIES745.9757.9826902.3989.3108912021328.310
          POINT-OF-CARE TESTING320.6333.3371.7415.5466.3525.4593.7671.712.6
          TOTAL1208.41237.21359.11496.51654.21835.92043.62277.710.9

          Target Audience

          • In Vitro Diagnostics Manufacturers : IVD companies need Europe-specific market data to develop localized product portfolios, navigate regulatory requirements, and identify high-growth country markets for cardiac marker testing solutions.
          • Healthcare System Administrators : Hospital networks and healthcare providers require market insights to optimize diagnostic testing protocols, budget allocation for cardiac diagnostics, and procurement strategies aligned with regional growth trends.
          • Investment & Private Equity Firms : Investors evaluating European healthcare diagnostics opportunities need detailed market sizing, growth projections, and competitive dynamics to assess investment viability and portfolio company potential.
          • Medical Device Distributors : Regional distributors and medical device suppliers require country-level market data to identify expansion opportunities, negotiate supplier agreements, and develop go-to-market strategies across European territories.
          • Healthcare Policy & Regulatory Bodies : Government health agencies and regulatory organizations need market intelligence to inform reimbursement policies, clinical guidelines, and healthcare infrastructure investments in cardiac diagnostics.

          Key Companies in the Europe Cardiac Marker Testing Market

          CompanyHQOwnershipStrongest segments
          ABBOTT LABORATORIESUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
          DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software),
          SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
          THERMO FISHER SCIENTIFICUnited StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
          BIO-RAD LABORATORIESUnited StatesPublic CompanyLife Science,Clinical Diagnostics,
          BIOMéRIEUX SAFrancePublic CompanyClinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA),
          BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems),
          DIASORIN SPAItalyPublic CompanyImmunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory,
          REVVITYUnited StatesPublic CompanyDiagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software,
          TOSOH CORPORATIONJapanPublic CompanyBasic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins),
          QUIDEL CORPORATIONUnited StatesPublic CompanyLabs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care,
          GUANGZHOU WONDFO BIOTECH CO., LTD.ChinaPublic CompanyRapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform,

          ABBOTT LABORATORIES

          Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.

          DANAHER CORPORATION

          Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.

          SIEMENS HEALTHINEERS AG

          Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.

          THERMO FISHER SCIENTIFIC

          Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.

          BIO-RAD LABORATORIES

          Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.

          BIOMéRIEUX SA

          bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.

          BECTON, DICKINSON AND COMPANY

          Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.

          DIASORIN SPA

          DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.

          REVVITY

          Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.

          TOSOH CORPORATION

          Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.

          QUIDEL CORPORATION

          Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.

          GUANGZHOU WONDFO BIOTECH CO., LTD.

          Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.

          Europe vs. other regions

          HowEurope compares to the other 3 regional blocs covered in this market.

          North America
          ~USD 2398.8 Million · 10.6% wtd CAGR ·
          Asia Pacific
          ~USD 1364.4 Million · 12.7% wtd CAGR ·
          Latin America
          ~USD 678.2 Million · 9.2% wtd CAGR ·
          Middle East & Africa
          ~USD 179.9 Million · 7.6% wtd CAGR ·

          Countries within Europe - compare and drill down

          Country2025 size (native)
          GermanyUSD 187.8 Million
          UKUSD 65.6 Million
          FranceUSD 218.1 Million
          ItalyUSD 137.4 Million
          SpainUSD 86.7 Million
          Rest Of EuropeUSD 103.2 Million

          Country market size visualization

          Germany
          USD 187.8 Million
          UK
          USD 65.6 Million
          France
          USD 218.1 Million
          Italy
          USD 137.4 Million
          Spain
          USD 86.7 Million
          Rest Of Europe
          USD 103.2 Million

          Reasons to Buy this Report

          • Regional Market Segmentation : Gain detailed insights into Europe's cardiac marker testing market with country-level breakdowns for Germany, France, Italy, Spain, UK, and Rest of Europe, enabling precise market targeting and localized strategy development.
          • Growth Trajectory Analysis : Understand the 11.7% CAGR driving Europe's market expansion from $861.5M to $1,494.9M by 2031, with comprehensive analysis of growth drivers specific to European healthcare dynamics and regulatory environments.
          • Competitive Landscape Intelligence : Identify key market players, emerging competitors, and strategic opportunities within Europe's cardiac diagnostics sector, with insights into regional market consolidation and partnership trends.
          • Healthcare Infrastructure Insights : Leverage detailed analysis of Europe's advanced healthcare systems, reimbursement policies, and regulatory frameworks to inform market entry strategies and product positioning across different European markets.
          • Demographic & Clinical Trends : Access comprehensive data on Europe's aging population, cardiovascular disease prevalence, and clinical adoption patterns driving demand for cardiac marker testing solutions across the region.

          Frequently asked questions

          What is the projected size of Europe's cardiac marker testing market by 2031?

          Europe's cardiac marker testing market is projected to reach $1,494.9 million by 2031, up from $861.5 million in 2026, representing an 11.7% compound annual growth rate.

          What factors are driving growth in Europe's cardiac marker testing market?

          Europe's market growth is driven by an aging population, rising cardiovascular disease prevalence, strong healthcare reimbursement policies, regulatory support, and increasing adoption of high-sensitivity diagnostic technologies.

          Which cardiac marker tests are most commonly used in Europe?

          Europe predominantly uses high-sensitivity troponin assays, B-type natriuretic peptide (BNP) tests, and multiplex biomarker panels integrated into clinical guidelines for acute coronary syndrome and heart failure diagnosis.

          How does Europe's cardiac marker testing market compare to other regions?

          Europe's 11.7% CAGR (2026–2031) reflects strong market maturity, advanced healthcare infrastructure, and high diagnostic adoption rates compared to emerging markets with lower penetration.

          What role do point-of-care testing devices play in Europe's cardiac marker market?

          Point-of-care cardiac marker testing is expanding in Europe due to faster turnaround times, improved patient outcomes in emergency settings, and integration into primary care and rural healthcare facilities.

          RESEARCH METHODOLOGY

          The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.

          Secondary Research

          In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

          Primary Research

          In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

          BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS

          Cardiac Marker Testing Market Size, and Share

          Note 1: Others include sales managers, marketing managers, and product managers.
          Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

          COMPANY NAME

          DESIGNATION

          Abbott Laboratories (US)

          Sales Manager

          F. Hoffmann-La Roche AG (Switzerland)

          Product Manager

          To know about the assumptions considered for the study, download the pdf brochure

          Market Size Estimation

          Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:

          • The key players in the industry have been identified through extensive secondary research
          • The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
          • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

          The research methodology used to estimate the market size includes the following:

          Cardiac Marker Testing Market Top Down and Bottom Up Approach

          Data Triangulation

          After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

          Market Definition

          Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).

          Key Stakeholders

          • Product Manufacturers, Distributors, and Suppliers
          • Diagnostic Laboratories and Point-of-care Testing Centers
          • Research Laboratories and CROs
          • Ambulatory Testing Centers
          • Contract Testing Laboratories
          • Academic Universities and Medical Research Centers
          • Research & Development (R&D) Centers

          Report Objectives

          • To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
          • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
          • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
          • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
          • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
          • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
          • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
          • To study the impact of AI on the market, along with the macroeconomic outlook for each region

          Available customizations:

          MarketsandMarkets offers the following customizations for this market report.

          Country Information

          • Additional country-level analysis of the cardiac marker testing market

          Company profiles

          • Additional five company profiles of players operating in the cardiac marker testing market.

          Product Analysis

          • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market

           

          Get the Full Cardiac Marker Testing Market Report

          Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.

          Download Sample Pages Buy Report

          METHODOLOGY

          Need a Tailored Report?

          Customize this report to your needs

          Get 10% FREE Customization

          Customize This Report
          Fact checked
          Cite this Research
          DMCA.com Protection Status